Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 6923.T and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 6923.T and 80,000+ other tickers.
See exactly how 6923.T's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6923.T and 80,000+ other tickers.
Stanley Electric Co., Ltd., established in Tokyo, Japan in 1920, is a global leader in the manufacturing, sales, and import/export of a diverse range of lighting solutions, particularly for the automotive sector. The company's operations are structured into three key divisions. Its Automotive Equipment Business provides advanced vehicle lighting, including LED, HID, and halogen headlamps, along with rear combination lamps, turn signals, and fog lights. The Electronic Components Business focuses on specialized LEDs (ultraviolet, visible light, and infrared), optical sensors, liquid crystal…
HOUSTON--(BUSINESS WIRE)--National Heat Treat (NHT) has achieved another success in its lawsuit against Defendants Robert Gutierrez, Fernando Gutierrez and Worldwide Heat Treat. Defendant Robert Gutierrez has been held in Contempt of Court for violation of the Temporary Restraining Order and the Temporary Injunction previously ordered against Defendants resulting from a hearing in Court on November 16, 2018. Sanctions were also assessed against Defendant Robert Gutierrez in the amount of $35,000, to be paid directly to the Plaintiff, National Heat Treat, by 5:00PM, June 14, 2019. The Court’s Order states if Defendant should further violate such Temporary Injunction, which “remains in full force and effect”, the Defendant Gutierrez may be fined and “confined for up to six months in the Harris County Jail.” NHT initially filed the case on August 31, 2018, when NHT sued Defendants Worldwide Heat Treat, Robert Gutierrez and his brother, Fernando Gutierrez of Worldwide Heat Treat, alleging Robert Gutierrez and his newly formed operation, “Worldwide Heat Treat,” had committed various unlawful actions including Theft, Misappropriation of Trade Secrets and Confidential Information, Tortious Interference with NHT’s Business Relations, Breach of Fiduciary Duty and Constructive Fraud, Unjust Enrichment and Conspiracy (full allegations are publicly filed in: Case No. 2018-59518 in the 11th District Court of Harris County, Texas). Included in such alleged unlawful actions, pursuant to NHT’s allegations, is conversion of NHT’s personal property (i.e., taking NHT’s property) and other alleged dishonest and unlawful conduct, as alleged in NHT’s Petition. NHT has already achieved numerous successes; the Court issued a Temporary Restraining Order against Robert Gutierrez, his brother Fernando and Worldwide Heat Treat signed by the court on August 31, 2018, in the same case. On October 1, 2018, the court again extended the TRO. Further, the Court conducted a temporary injunction hearing and entered an order in favor of NHT granting a temporary injunction against Defendants on November 16, 2018, which is in place until the time of trial (Order file stamped December 5, 2018). Monday’s ruling of Contempt relates to the Court’s finding that Defendants violated the TRO and the Temporary Injunction, specifically noting, “With actual knowledge of the Temporary Restraining Order and the Temporary Injunction, Defendant Gutierrez willingly, knowingly, and intentionally violated the Temporary Restraining Order and Temporary Injunction.” The Contempt Order can be found here and details the sanctions levied by the Court against Defendant Robert Gutierrez. About National Heat Treat National Heat Treat (NHT) is headquartered in Houston, Texas. It provides proprietary heat treat services and testing services for a variety of metals and applications. National Heat Treat provides its customers with heat treating experts who have more than 100 years of combined experience. NHT serves companies involved in all heat-treating processes including oil and gas (upstream, midstream, downstream), automotive, aviation, power generation, construction and all heavy equipment industries. National Heat Treat’s areas of specialties include, among other specialties, carbonitriding, vacuum age, vacuum/vacuum solution anneal, atmosphere hardening, atmosphere normalize processes, atmosphere anneal, box furnace tempering, car bottom furnace tempering, and the ability to stress relieve, anneal, shrink fit, bake, and burn-off all materials. The company is located at 6923 Brittmore Road, Houston, Texas 77041.
HOUSTON--(BUSINESS WIRE)--National Heat Treat (NHT) has achieved success in its lawsuit, pursuant to which, on August 31, 2018, NHT sued Worldwide Heat Treat, Robert Gutierrez and his brother, Fernando Gutierrez of Worldwide Heat Treat, in court. NHT has alleged that Robert Gutierrez and his newly formed operation, “Worldwide Heat Treat,” have committed various unlawful actions including Theft, Misappropriation of Trade Secrets and Confidential Information, Tortious Interference with NHT’s Business Relations, Breach of Fiduciary Duty and Constructive Fraud, Unjust Enrichment and Conspiracy (full allegations are publicly filed in: Cause No. 2018-59518 in the 11th District Court of Harris County, Texas). Included in such alleged unlawful actions, pursuant to NHT’s allegations, is conversion of NHT’s personal property (i.e., taking NHT’s property) and other alleged dishonest and unlawful conduct, as alleged in NHT’s Petition. NHT has already achieved success; the Court issued a Temporary Restraining Order against Robert Gutierrez, his brother Fernando and Worldwide Heat Treat signed by the court on August 31, 2018, in the same case. On October 1, 2018, the court again extended the TRO which remains in effect. The Order which can be found here: www.TRO-Orders10-22-2018.com states in favor of NHT, prohibits Robert Gutierrez and Worldwide Heat Treat from selling, transferring, using NHT’s personal property, any NHT property located at WHT’s places of business, and any NHT property located at Defendants’ residences. Pursuant to the allegations in the suit, NHT alleges Robert Gutierrez and Worldwide Heat Treat are also tortiously interfering with NHT’s business and misleading customers, as to whether Worldwide Heat Treat is actually certified under ISO 9001-2008. About National Heat Treat National Heat Treat (NHT) is headquartered in Houston, Texas. It provides proprietary heat treat services and testing services for a variety of metals and applications. National Heat Treat provides its customers with heat treating experts who have more than 100 years of combined experience. NHT serves companies involved in all heat-treating processes including oil and gas (upstream, midstream, downstream), automotive, aviation, power generation, construction and all heavy equipment industries. National Heat Treat’s areas of specialties include, among other specialties, carbonitriding, vacuum age, vacuum/vacuum solution anneal, atmosphere hardening, atmosphere normalize processes, atmosphere anneal, box furnace tempering, car bottom furnace tempering, and the ability to stress relieve, anneal, shrink fit, bake, and burn-off all materials. The company is located at 6923 Brittmore Road, Houston, Texas 77041.
LONDON--(BUSINESS WIRE)--SpendEdge, a global procurement intelligence advisory firm, has announced the completion of their most recent whitepaper on how procurement intelligence helps businesses reinvent their value chains. Procurement officials of leading organizations are now looking at leveraging solutions that utilize AI to streamline processes and improve decision-making across their supply chain. In today’s competitive market scenario, procurement intelligence is the key to establishing long-term strategic plans. Moreover, implementing AI in supply chain functions helps businesses to innovate and grow faster. However, businesses need to understand how to harness maximum benefits of AI to gain a competitive advantage. According to the procurement experts at SpendEdge, “Procurement technology vendors are increasingly focusing on developing solutions that use AI including cognitive procurement advisors (CPAs) and virtual personal assistants (VPAs) that help in increasing business efficiency.” Request a free proposal to see how SpendEdge’s procurement solutions can help you. Best practices to reinvent value chains with the power of AI: Supply management – It is essential to monitor supply chain processes to ensure the supplier-relationships are bringing in value to the organization. Machine learning & risk management – Machine learning techniques help firms to uncover new trends and key data relationships, which in turn assist in risk reduction. Natural language processing (NLP) – NLP plays a significant role in streamlining auditing and compliance actions. To read more, download this whitepaper Download the complete procurement intelligence whitepaper here: https://www.spendedge.com/request-white-paper?related=6923 About SpendEdge SpendEdge shares your passion for driving sourcing and procurement excellence. We are a preferred procurement market intelligence partner for Fortune 500 firms and other leading companies across numerous industries. Our strength lies in delivering robust, real-time procurement market intelligence that helps sourcing and procurement professionals make informed decisions. These innovative procurement solutions help enterprises transform structural capabilities, improve execution efficiency, and fast-track time to savings.
SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis, today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. The Company intends to use the net proceeds from the offering for commercialization of Mytesi®—an FDA-approved human prescription drug product of Jaguar’s wholly-owned subsidiary, Napo Pharmaceuticals, Inc., as well as for general corporate purposes and working capital. Maxim Group LLC is acting as the sole book-running manager for the offering. WestPark Capital, Inc. is acting as co-manager. The shares of common stock referred to above are being offered under the Company's shelf registration statement on Form S-3 (No. 333-220236), including a base prospectus, previously filed with and declared effective by the U.S. Securities and Exchange Commission (SEC). The shares are being offered by means of a prospectus supplement and accompanying prospectus, forming part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus related to the offering, along with a free writing prospectus, have been filed with the SEC and are available on the website of the SEC at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement, accompanying prospectus and free writing prospectus also may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at (800) 724-0761. For more information regarding this offering, you can contact Maxim Group LLC at 800-537-6923 and refer to the Jaguar offering. Before you invest, you should carefully read the preliminary prospectus supplement and the accompanying prospectus in that registration statement and other documents Jaguar has filed or will file with the SEC for more complete information about Jaguar and the offering. Conference Call and Web Presentation Details: The Company's management will host a conference call to present the investment opportunity on September 20th, 2017 at 2 p.m. Eastern Time. Participants should dial into the call 10 minutes before the scheduled time by dialing 800-346-7359 and using entry code 349271. A copy of the Company’s presentation can be accessed via the following link: www.dealroadshow.com/retail. Click on the Jaguar Health, Inc. presentation link thereafter. This presentation may include forward-looking statements that reflect the Company’s current views with respect to future events and financial performance. These views may be based on a number of assumptions and are subject to various risks. Such forward-looking statements are not guarantees of future performances and no assurance can be given that any future events will occur, that projections will be achieved or that the Company’s assumptions will prove to be correct. Actual results may differ materially from those projected, and the Company does not undertake to revise any such forward-looking statements to reflect future events or circumstances. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About Mytesi® Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%). More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity. About Jaguar Health, Inc. Jaguar Health, Inc. is a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Mytesi® is in development for multiple possible follow-on indications, including chemotherapy-induced diarrhea; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease (IBD); irritable bowel syndrome (IBS); and as a second-generation anti-secretory agent for use in cholera patients. Canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. Equilevia™ is Jaguar’s non-prescription product for total gut health in equine athletes. Canalevia™ and Equilevia™ contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are Jaguar’s lead non-prescription animal products. Mytesi®, Canalevia™, Equilevia™ and Neonorm™ are distinct products that act at the same last step in a physiological pathway generally present in mammals. For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com. Forward-Looking Statements Certain statements in this press release constitute “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. These include statements regarding the development of potential Mytesi® follow-on indications, the proposed public offering, the expected gross proceeds from the offering, and the use of proceeds from the offering. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Jaguar-JAGX
STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Pandox has entered in to an agreement to divest the hotel property Scandic Antwerp in Belgium for MEUR 16, to the hotel chain Van Der Valk from the Netherlands. The transaction is in form of a sale of the hotel property Scandic Antwerp (Land register of Antwerp, 24th division, Borgerhout 1st division, Article 6923, series A 226/05/6) in Antwerp Belgium, in a company with an underlying property value of MEUR 16, which is in line with the most recent valuation. Pandox will receive net proceeds of MEUR 13.6 after deduction of deferred tax. The transaction will close and the property will be vacated 1 December, 2015. “When our partner Scandic decided to not extend the lease agreement for the hotel property, it was a natural step for Pandox to explore various options, including a divestment. We are pleased to have reached an agreement with Van Der Valk to divest the hotel”, says Anders Nissen, CEO at Pandox. Pandox AB (publ) is required to publish this information under the Swedish Securities Market Act and/or Financial Instruments Trading Act. The information was submitted for publication on 29 September 2015 at 14:50 CEST. About Pandox Pandox is a leading owner of hotel properties in Northern Europe with a focus on sizeable hotels in key leisure and corporate destinations. Pandox’s hotel property portfolio comprises 104 hotels with approximately 22,000 hotel rooms across eight countries. Pandox’s business is organised into Property management, which comprises hotel properties leased on a long-term basis to market leading regional hotel operators and leading international hotel operators, and Operator activities, which comprises hotel operations executed by Pandox in its owner-occupied hotel properties. Pandox was founded in 1995 and the company’s B shares are, as of 18 June 2015, listed on Nasdaq Stockholm. www.pandox.se This information was brought to you by Cision http://news.cision.com